Abstract
Many of the plant-derived compounds used in chemotherapies are currently produced by semisynthesis, which results in limited supplies at exorbitant market prices. However, the synthetic biology era, which began ca 15 years ago, has progressively yielded encouraging advances by using engineered microbes for the practical production of cheaper plant anticancer drugs.
Highlights
Many of the plant-derived compounds used in chemotherapies are currently produced by semisynthesis, which results in limited supplies at exorbitant market prices
Considerable effort is being made in this area, and given the successes with the production of other plant-derived compounds in yeast, we are optimistic that microbial cell factories will be soon available for participation in lower-cost production processes of Monoterpene Indole Alkaloids (MIAs)-based anticancer formulations
A few recent works have demonstrated the feasibility of production platforms for several families of plant-derived anticancer drugs – that is, opioids, cannabinoids, and alkaloids – and these successes suggest that we can anticipate the same for taxanes and lignans (Figure 1)
Summary
Many of the plant-derived compounds used in chemotherapies are currently produced by semisynthesis, which results in limited supplies at exorbitant market prices. Plant-Derived Anticancer Drugs: Low Supply, High Cost Plants represent a seemingly inexhaustible source of biologically active compounds.
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Disclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.